{
 "drug": "Palbociclib Capsule",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "04/22/2026",
 "dayN": 125,
 "cat": "Oncology",
 "companies": [
  "Pfizer Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "04/22/2026",
   "update_type": "New",
   "initial_posting_date": "04/22/2026",
   "package_ndc": "0069-0187-21",
   "generic_name": "Palbociclib Capsule",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet \nNDC 0069-0284-03 will continue to be manufactured.",
   "openfda": {
    "application_number": [
     "NDA207103"
    ],
    "brand_name": [
     "IBRANCE"
    ],
    "generic_name": [
     "PALBOCICLIB"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-0187",
     "0069-0188",
     "0069-0189"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "PALBOCICLIB"
    ],
    "rxcui": [
     "1601380",
     "1601386",
     "1601388",
     "1601390",
     "1601392",
     "1601394"
    ],
    "spl_id": [
     "7dcc9b87-0aa4-4a00-aced-96be3553e8ac"
    ],
    "spl_set_id": [
     "e0e6412f-50b4-4fd4-9364-62818d121a07"
    ],
    "package_ndc": [
     "0069-0187-21",
     "0069-0188-21",
     "0069-0189-21"
    ],
    "nui": [
     "N0000175605",
     "N0000175082",
     "N0000190114"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]"
    ],
    "unii": [
     "G9ZF61LE7G"
    ]
   },
   "update_date": "04/22/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Capsule",
   "presentation": "Ibrance, Capsule, 75 mg (NDC 0069-0187-21)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "04/22/2026",
   "update_type": "New",
   "initial_posting_date": "04/22/2026",
   "package_ndc": "0069-0188-21",
   "generic_name": "Palbociclib Capsule",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.",
   "openfda": {
    "application_number": [
     "NDA207103"
    ],
    "brand_name": [
     "IBRANCE"
    ],
    "generic_name": [
     "PALBOCICLIB"
    ],
    "manufacturer_name": [
     "Pfizer Laboratories Div Pfizer Inc"
    ],
    "product_ndc": [
     "0069-0188",
     "0069-0187",
     "0069-0189"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "PALBOCICLIB"
    ],
    "rxcui": [
     "1601380",
     "1601386",
     "1601388",
     "1601390",
     "1601392",
     "1601394"
    ],
    "spl_id": [
     "7dcc9b87-0aa4-4a00-aced-96be3553e8ac"
    ],
    "spl_set_id": [
     "e0e6412f-50b4-4fd4-9364-62818d121a07"
    ],
    "package_ndc": [
     "0069-0187-21",
     "0069-0188-21",
     "0069-0189-21"
    ],
    "nui": [
     "N0000175605",
     "N0000175082",
     "N0000190114"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]"
    ],
    "unii": [
     "G9ZF61LE7G"
    ]
   },
   "update_date": "04/22/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Capsule",
   "presentation": "Ibrance, Capsule, 100 mg (NDC 0069-0188-21)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  }
 ]
}